Postoperative Pain Market
Adoption of Postoperative Pain treatments to be Driven by Invasive and Non-invasive Operations. For More, Read the Exclusive Report on Postoperative Pain by FMI
Postoperative Pain Market By Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Postoperative Pain Market Outlook (2023 to 2033)
The global postoperative pain market size is estimated to be valued at US$ 38.43 billion in 2023 and is projected to surpass a valuation of US$ 63.8 billion by 2033. The adoption of postoperative pain drugs is likely to rise at a CAGR of 5.2% during the forecast period. Some major factors propelling the postoperative pain industry growth include:
- The market for postoperative pain is likely to expand due to the increased demand for pain management drugs and equipment.
- Worldwide, the number of cancer patients having surgery is rising which is driving the market expansion.
- Due to the sluggish healing processes associated with aging and medical patients' procedures, postoperative pain management is required.
- Demand for postoperative pain treatment is anticipated to be driven by an increase in the number of traffic accidents, relative trauma injuries, and area unit needs for pain management following surgeries.
- Postoperative pain management, however, can help with severe pain and soreness.
These factors are propelling the major players to increase their output, which is likely to ultimately result in positive market growth for postoperative pain.
Let us know your requirement to get
100% FREE customization
Adoption of Postoperative Pain Therapeutics Likely to be Fueled by High Incidence and Severity of Postoperative Pain
According to health experts, surgery is linked to long-lasting chronic postoperative pain that typically lasts between three and six months. The demand for postoperative pain is anticipated to rise as phantom pain is one of the frequent postoperative disorders that follows breast surgery, a cesarean section, a thoracotomy, limb amputation, or inguinal hernia repair. Numerous studies carried out in nations with highly established healthcare systems have shown that between one-third and fifty percent of patients do not have adequate postoperative pain management.
Introduction of Promising Drugs, and High Adoption Rate of Pain Management in Developed as well as Emerging Countries
The global market for postoperative pain treatments is predicted to experience growth over the forecast period due to an increase in surgical procedures and the intensity of postoperative pain. The global postoperative pain treatment market is anticipated to grow as a result of the development of numerous novel medications. Wide safety margins and advantageous characteristics are being used in the development of new medications.
The importance of non-opioid adjuncts and alternatives has increased for postoperative pain management. Examples of medications that have been popular in the postoperative pain market include intravenous (IV) acetaminophen, non-steroidal anti-inflammatory medicines (NSAIDs), magnesium, ketamine, dexmedetomidine, and liposomal bupivacaine. As a result, postoperative pain therapies now predominate in both emerging and developed markets due to innovative drugs, rising demand, better access, and improved pain management.
|
Postoperative Pain Market Size (2023) |
US$ 38.43 billion |
|
Postoperative Pain Projected Market Value (2033) |
US$ 63.8 billion |
|
Global Postoperative Pain CAGR (2023 to 2033) |
5.2% |
|
Market Share of Top 5 Countries |
65% |
Find your sweet spots for generating winning opportunities in this market.
Talk to Analyst2018 to 2022 Postoperative Pain Market Outlook in Comparison to 2023 to 2033 Forecast
Historically, the demand for postoperative pain drugs increased at a CAGR of 4.7% from 2018 to 2022. The market for postoperative pain was worth US$ 30.4 billion in 2018, the market surpassed US$ 36.53 billion by 2022. The demand for postoperative pain treatment is anticipated to increase in the future due to an increase in the number of traffic accidents, relative trauma injuries, and relative trauma injuries.
| Attribute | Valuation |
| 2025 | US$ 42.53 billion |
| 2028 | US$ 49.52 billion |
| 2032 | US$ 60.65 billion |
The market is anticipated to grow at a CAGR of 5.2% from 2023 to 2033, surpassing US$ 63.8 billion by 2033.
- Short Term (2022 to 2025): The demand for postoperative pain treatment techniques is increasing due to factors such as the prevalence of chronic disease, the increase in surgical procedures, the demand for novel non-opioid analgesics in postoperative pain therapy, and raising awareness of palliative care.
- Medium Term (2025 to 2028): The excessive consumption of painkillers is mostly caused by the increasing number of surgeries performed around the world. Similar to how the prevalence of cancer therapy-related pain is rising, the market is projected to grow due to an aging and growing pediatric population having various sorts of surgeries.
- Long Term (2028 to 2032): Postoperative discomfort can assist manage severe pain and soreness. Due to these factors, the major manufacturers are projected to boost their production, which will ultimately result in favorable growth for the postoperative pain market.
Comparative View of the Adjacent Postoperative Pain Market
Postoperative Pain Market:
|
Attributes |
Postoperative Pain Market |
|
CAGR (2023 to 2033) |
5.2% |
|
Market Value (2033) |
US$ 63.8 billion |
|
Opportunity |
The development of non-opioid pharmaceuticals with a novel drug delivery strategy for extended-release of medications is the main focus of drug manufacturers. |
|
Trends |
Growing demand for surgical operations and rising public awareness of postoperative pain control |
Pain Management Devices Market:
|
Attributes |
Pain Management Devices Market |
|
CAGR (2023 to 2033) |
9% |
|
Market Value (2033) |
US$ 18.0 billion |
|
Opportunity |
The demand for muscle and nerve stimulators has increased as lifestyle problems like obesity and diabetes are becoming more common. |
|
Trends |
A significant aspect that is predicted to contribute to the market's growth is the rising incidence of trauma or hypertension. |
Pain Management Drugs Market:
|
Attributes |
Pain Management Drugs Market |
|
CAGR (2023 to 2033) |
3.9% |
|
Market Value (2033) |
US$ 115.24 billion |
|
Opportunity |
Age-related disorders such as joint pain and other chronic illnesses are more common in older people and are a major driver for growth in the global market for pain management drugs. |
|
Trends |
Increased incidence of chronic conditions like cancer, diabetic neuropathy, and osteoarthritis fuels market expansion. |
A unified Market Research Subscription Platform, built for today's disparate research needs.
Country-wise Insights
United States to Witness High Growth in the Postoperative Pain Industry
According to projections, the USA is likely to control 87.9% of the market for postoperative pain in North America by 2022. The adoption of opioid treatment is anticipated to lessen the opioid epidemic's rising prevalence in North America, particularly in the United States. For instance, more than 200 million opioid medications were prescribed and given to patients in the United States in 2018.
Furthermore, it is anticipated that the usage of postoperative pain medications would rise in this region due to the strong drug pipeline with effective medications up for FDA clearance. Patients' attitudes have improved in the United States as a result of better compliance with pain treatment suggestions. The country's demand for postoperative pain management pharmaceuticals is probably going to rise as a result of these figures, which will help the industry grow.
Several industry participants are putting strategic plans into action, which is helping the market expand. For instance, Allay Therapeutics, a clinical-stage biotechnology company that has been at the forefront of developing ultra-sustained analgesic products to revolutionize postsurgical pain management and recovery, released the first-ever clinical data demonstrating non-opioid pain relief lasting two weeks after a single administration in May 2021.
Germany to Lead European Postoperative Pain
In 2022, Germany is anticipated to represent 26.9% of the market for postoperative pain in Europe. The market has grown due to the increasing prevalence and severity of postoperative pain, the launch of promising medications, an increase in surgical operations, and a high rate of pain procedures in developed nations like Germany.
Demand for postoperative pain medications is rising across Germany as opioid maintenance therapy (OMT) for treating opioid dependence (OD) becomes more widely accepted.
South Korea's Postoperative Pain Treatment Demand is Being Driven by a High Number of Surgeries
Due to the country's rising surgical rate, the postoperative pain market in South Korea is anticipated to grow at a 6.3% CAGR during the forecast period. Many manufacturers of painkillers are forming partnerships, and distribution agreements, and introducing postoperative painkillers in Korea. To increase their position in the worldwide market, major market players are concentrating on various business methods, such as obtaining product approval from regulatory bodies. On May 1, 2018, Grunenthal and Mundipharma struck a distribution and license deal, enabling Mundipharma to market and sell Grunenthal's Tramal (tramadol).
Japan Postoperative Pain Industry to Witness Growth Limiting and Factors
In Japan, opioids are usually prescribed for postoperative pain, but due to an increase in opioid use for non-medical reasons, governing bodies are pressuring doctors to prescribe non-opioid medications, which presents an opportunity for businesses to launch novel non-opioid medications. However, rising concerns about the opioid epidemic in the region and the rising burden of pain on providers of reimbursement are projected to limit the market's ability to grow to some extent.
Category-wise Insights
Which Class of Drugs Has the Most Influence in the Postoperative Pain Industry?
By drug class, the opioids segment is predicted to grow at a 4% CAGR throughout the projection period to represent a significant proportion of 61.3% in 2022.
Adults who experience moderate to severe post-operative pain are typically treated with opioids, according to the NIH. As a result, over the past ten years, opioid use has increased. Opioid medications are recognized to be useful for treating postoperative pain and have demonstrated the capacity to support patients in accomplishing their clinical goals based on research studies and current trials.
Which Route of Administration Holds the Dominance in the Market?
High Demand for Oral Postoperative Pain Procedures
Oral postoperative pain is anticipated to hold 37.8% of the market in 2022 in terms of route of administration. For patients, especially the elderly, the oral route of administration is more convenient and widely accepted, which contributes to a bigger market share in the postoperative pain market. The high share of the market is ascribed to the segment's simplicity and patients' preference for oral drug administration.
What are the Players in the Postoperative Pain Industry Doing?
Leading providers of postoperative pain medications are collaborating and acquiring other pharmaceutical firms as their primary approach for the creation of new product lines of pain medications. The demand for painkiller pharmaceuticals is increasing as key stakeholders put more emphasis on the creation of abuse-deterrent opioid drugs and the launch of extended-release non-opioid drugs for post-surgery pain. Similar to this, greater non-narcotic drug discovery and commercialization as well as growing awareness of post-surgery pain management are supporting market expansion.
The market is anticipated to expand as a result of rising acute disease prevalence and an increase in the elderly population in emerging economies. Manufacturers of painkilling drugs should expect great opportunities as patient awareness of procedures and operations grows and as research into pain management expands. Market expansion is anticipated to expand as government efforts to encourage improved postoperative pain management increase.
Key Players in the Postoperative Pain Industry
- Novartis AG
- Allergan plc
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V
- Pfizer Inc.
- Purdue Pharma L.P
- Janssen Pharmaceuticals, Inc.
- Endo International plc
- Pacira Pharmaceuticals Inc.
- Egalet Corporation
- GlaxoSmithKline Plc.
Recent Developments in the Postoperative Pain Industry:
- Zyla Life Sciences purchased Assertio Therapeutics, Inc. in May 2020. Due to this, a developing commercial pharmaceutical business was able to expand its line of neurology, inflammation, and pain medications.
- The commercialization of ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures was announced by Health Canada in March 2022, according to Heron Therapeutics, Inc.
- The perioperative long-acting analgesic medication CPL-01 underwent a Phase IIb study in March 2022, and Cali Biosciences Co., Ltd., a biopharmaceutical firm focused on the discovery and development of novel pharmaceuticals, announced positive results.
Postoperative Pain Market Report Scope
|
Attribute |
Details |
|
Forecast Period |
2023 to 2033 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ billion for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Postoperative Pain Industry Survey by Category
By Drug Class:
- Opioids
- NSAIDs
- Local Anesthetic
- Acetaminophen
By Route of Administration:
- Injectable
- Oral
- Topical
- Transdermal
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
What is the Current Postoperative Pain Market Size?
The postoperative pain market size is anticipated to be US$ 38.43 billion in 2023.
How Big is the Postoperative Pain Market?
The postoperative pain market size is assessed to be US$ 63.8 billion in 2033.
At what rate is the Postoperative Pain Market expected to rise?
The postoperative pain market is expected to rise at a CAGR of 5.2% during the forecast period.
Which Region Dominates the Postoperative Pain Market?
The United States is projected to lead the postoperative pain market over the forecast period.
Table of Content
1. Executive Summary | Postoperative Pain Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Opioids 5.3.2. NSAIDs 5.3.3. Local Anaesthetics 5.3.4. Tricyclic Antidepressants 5.3.5. Antiepileptic Drugs 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Intravenous 6.3.3. Intramuscular 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. The United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. The USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. The United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Menarini Group 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. AcelRx Pharmaceuticals 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Trevena, Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Heron Therapeutics 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Innocoll Pharmaceuticals 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. DURECT Corporation 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Pacira Pharmaceuticals 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Baudax Bio 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Bausch & Lomb 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Novartis Pharmaceuticals 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Eli Lilly and Company 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. Teva Pharmaceutical Industries Ltd. 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. Formosa Pharmaceuticals 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 4: Global Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033 Table 5: North America Market Value (US$ million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 7: North America Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 8: North America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033 Table 9: Latin America Market Value (US$ million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 11: Latin America Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 12: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033 Table 13: Europe Market Value (US$ million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 15: Europe Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 16: Europe Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033 Table 17: South Asia Market Value (US$ million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 19: South Asia Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 20: South Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033 Table 21: East Asia Market Value (US$ million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 23: East Asia Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 24: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033 Table 25: Oceania Market Value (US$ million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 27: Oceania Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 28: Oceania Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033 Table 29: MEA Market Value (US$ million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ million) Forecast by Drug Class, 2018 to 2033 Table 31: MEA Market Value (US$ million) Forecast by Route of Administration, 2018 to 2033 Table 32: MEA Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 3: Global Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 4: Global Market Value (US$ million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 11: Global Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 14: Global Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033 Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 22: North America Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 23: North America Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 24: North America Market Value (US$ million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 31: North America Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 34: North America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 42: Latin America Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 43: Latin America Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 44: Latin America Market Value (US$ million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 51: Latin America Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 54: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 62: Europe Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 63: Europe Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 64: Europe Market Value (US$ million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 71: Europe Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 74: Europe Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033 Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 82: South Asia Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 83: South Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 84: South Asia Market Value (US$ million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 91: South Asia Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 94: South Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 99: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 102: East Asia Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 103: East Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 104: East Asia Market Value (US$ million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 111: East Asia Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 114: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 122: Oceania Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 123: Oceania Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 124: Oceania Market Value (US$ million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 131: Oceania Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 134: Oceania Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033 Figure 139: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ million) by Drug Class, 2023 to 2033 Figure 142: MEA Market Value (US$ million) by Route of Administration, 2023 to 2033 Figure 143: MEA Market Value (US$ million) by Distribution Channel, 2023 to 2033 Figure 144: MEA Market Value (US$ million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ million) Analysis by Drug Class, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 151: MEA Market Value (US$ million) Analysis by Route of Administration, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 154: MEA Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033 Figure 159: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
